Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4826908 | 0.85 | CYP1A2 (0.55) | HPGDRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL28816871 | 0.83 | MAPK1 (0.45) | RAB9ANPC1MAPTKDM4EALDH1A1 | |
| SCHEMBL10620579 | 0.83 | CA1 (0.54) | HPGDRAB9ANPC1MAPTKDM4E | |
| SCHEMBL4827992 | 0.81 | HPGD (0.49) | HPGDRAB9ANPC1MAPTKDM4E | |
| SCHEMBL4826296 | 0.81 | P2RX4 (0.49) | HPGDRAB9ANPC1MAPTKDM4E | |
| SCHEMBL4825991 | 0.81 | HPGD (0.49) | HPGDRAB9ANPC1MAPTKDM4E | |
| SCHEMBL2095473 | 0.80 | HPGD (0.58) | HPGDRAB9ANPC1MAPTKDM4E | |
| SCHEMBL2089909 | 0.80 | HPGD (0.70) | HPGDRAB9ANPC1MAPTKDM4E | |
| SCHEMBL31645535 | 0.78 | HPGD (0.43) | HPGDRAB9ANPC1ALDH1A1MAPK1 | |
| SCHEMBL3785145 | 0.78 | EGFR (0.54) | HPGDRAB9ANPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439382-B2 | 4-alkyl-2-haloaniline derivatives and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20050143454-A1 | 4-Alkyl-2-haloaniline derivative and process and process for producing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2005-06-30 | — | — | US | disclosed |
| EP-1506954-A1 | 4-ALKYL-2-HALOANILINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143454-A1 | 4-Alkyl-2-haloaniline derivative and process and process for producing the same | NAT1, CYP4X1, HAX1 | HPGD 1153/4885RAB9A 811/4885NPC1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.